Pinned Tweet
So honored to serve as a Featured Voice for #ASCO25 among amazing colleagues ✨
Excited to share the latest data and key takeaways from the meeting
@OncBrothers @yekeduz_emre @drenriquegrande @DRBakaloudiMD @realbowtiedoc @ReginaBarCar @crisbergerot @ReneeSaliby @MikeSerzanMD
@OncoAlert
Excited to share the latest data and key takeaways from the meeting
@OncBrothers @yekeduz_emre @drenriquegrande @DRBakaloudiMD @realbowtiedoc @ReginaBarCar @crisbergerot @ReneeSaliby @MikeSerzanMD
@OncoAlert
Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25
1
4
31
2,133
Bárbara Melão, MD, PhD retweeted
News From Industry: TALAPRO Update in #ProstateCancer
Source Businesswire and Pfizer
buff.ly/HTeEtmv
Pfizer reports the Phase 3 TALAPRO-3 trial showed that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in patients with hormone-sensitive prostate cancer, exceeding the target hazard ratio. Benefits were consistent across BRCA and non-BRCA mutations. An interim analysis indicated a strong trend toward improved overall survival.
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin
@nataliagandur @acampsmalea @BRicciutiMD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago
Source Businesswire and Pfizer
buff.ly/HTeEtmv
Pfizer reports the Phase 3 TALAPRO-3 trial showed that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in patients with hormone-sensitive prostate cancer, exceeding the target hazard ratio. Benefits were consistent across BRCA and non-BRCA mutations. An interim analysis indicated a strong trend toward improved overall survival.
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin
@nataliagandur @acampsmalea @BRicciutiMD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago
0
12
24
1,850
We are all looking forward to #GU26
Dear Colleaguest at #GU26
WELCOME TO San Francisco
We Are All @OncoAlert 🚨
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 thiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago
0
4
6
501
BRCAAway Ph2 Trial #ASCOGU26
Greater benefit with 1L Abi+Olaparib combination
@OncoAlert @psalustiano @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett @to_be_elizabeth @ADesaiMD
Greater benefit with 1L Abi+Olaparib combination
@OncoAlert @psalustiano @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett @to_be_elizabeth @ADesaiMD
BRCAAway final OS update.
Front-line combination mattered.
Sequential therapy did not catch up.
Phase 2.
But a clear signal.
Test early.
Treat early.
#gu26 #cancer #oncology
@OncoAlert @ASCO @medicalwatchBC
@DrChoueiri @yekeduz_emre @neerajaiims @CParkMD @Silke_Gillessen biah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal @crisbergerot @DrDanielHeng @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @tompowles1 @BraunMDPhD @uromigos @MattGalsky @apolo_andrea
@bavilima @SuyogCancer @ONCOassist @gbanna74 @NazliDizman @MedicalwatchFTW @OncLive @urologysummit @IMG_Oncologists @AmandaBinDC @sarah_c_hopkins @MikeSerzanMD
0
9
19
940
Post-op RT + HT.
Benefit mainly when pre-RT PSA >0.5.
For most, short-term HT is enough.
But at PSA >0.5, many are PSMA PET positive?
Old trials. New imaging.
Selection is everything.
@AmarUKishan @DrSpratticus @piet_ost
#gu26 #cancer #oncology
@oncoalert @ASCO @ASCOcalwatchBC
@DrChoerajaiims @CParkMD @Silke_Gillessen @PGrivasMDPhD @VivekSubbiah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal @crisbergerot @DrDanielHeng @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @tompowles1 @BraunMDPhD @uromigos @MattGalsky @apolo_andrea
@bavilima @SuyogCancer @ONCOassist @gbanna74 @NazliDizman @MedicalwatchFTW @OncLive @urologysummit @IMG_Oncologists @AmandaBinDC @sarah_c_hopkins @MikeSerzanMD
0
4
9
694
Bárbara Melão, MD, PhD retweeted
💫🌟FDA Approves IsoPSA® — a new blood-based test to refine biopsy decisions in prostate cancer
@OncoAlert @APCCC_Lugano @MedicalwatchHQ
IsoPSA (Cleveland Diagnostics) becomes the first structure-based PSA assay approved via PMA, offering more accurate risk assessment for cer. Key points 👇
🔵 Detects cancer-specific structural variants of the PSA protein
🔵 Indicated for men ≥50 with elevated PSA considering biopsy
🔵 Based on large prospective multicenter study (14 sites, US)
🔵 Aims to reduce unnecessary biopsies — up to 75% currently negative
🔵 Already included in NCCN 2025 & AUA/SUO 2023 guidelines
🔵 Builds on the IsoClear™ protein-structure platform
A meaningful step toward precision early detection
@genentech @abbvie @ASCO @Movember @urologysummit @UCSFCancer businesswire.com/news/home/2025…
#ProstateCancer #EarlyDetection #PrecisionOncology #GUOnc #OncoTwitter
@OncoAlert @APCCC_Lugano @MedicalwatchHQ
IsoPSA (Cleveland Diagnostics) becomes the first structure-based PSA assay approved via PMA, offering more accurate risk assessment for cer. Key points 👇
🔵 Detects cancer-specific structural variants of the PSA protein
🔵 Indicated for men ≥50 with elevated PSA considering biopsy
🔵 Based on large prospective multicenter study (14 sites, US)
🔵 Aims to reduce unnecessary biopsies — up to 75% currently negative
🔵 Already included in NCCN 2025 & AUA/SUO 2023 guidelines
🔵 Builds on the IsoClear™ protein-structure platform
A meaningful step toward precision early detection
@genentech @abbvie @ASCO @Movember @urologysummit @UCSFCancer businesswire.com/news/home/2025…
#ProstateCancer #EarlyDetection #PrecisionOncology #GUOnc #OncoTwitter
1
16
33
4,984
Bárbara Melão, MD, PhD retweeted
👏 Excellent discussion by @bavilima & @dandanmena — exploring Lutetium PSMA, BULLSEYE, and Terbium vs Lutetium insights.
All the key questions clinicians should be discussing in PSMA-targeted advanced prostate cancer 💬@OncoAlert
All the key questions clinicians should be discussing in PSMA-targeted advanced prostate cancer 💬@OncoAlert
Dear Colleagues at #ESMO25
Oncology: Here & Now is BACK ‼️
S2E1 GU Oncology
Here they discuss Lutetium PSMA or Deferred ADT
Listen Here: youtu.be/FSrJ5iL3F-c?si…
Join @bavilima 🇧🇷& @dandanmena 🇲🇽 on this Great Webcast as they discuss #ProstateCancer :
✅Rationale between BULLSEYEween Lutetium & Terbium
✅Affinity🆚Toxicity
✅FU of patients with PET
and much much more..AVAILABLE NOW!!!
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas
@yekeduz_emre @DrYukselUrun
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
0
2
5
747
The OncoAlert🚨Round Up Day Two of #ESMO25
REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…
Discussing:
OUR TOP 5⃣ PICKS Presented Oct 18, 2025
⭐️DESTINY Breast 11 (291O)
⭐️DESTINY Breast 5 (LBA 1)
⭐️evERA (LBA 16)
⭐️RAMPART ( LBA93 )
⭐️KEYNOTE-905 ( LBA2 )
ahua
@UOzkerim
@DrMirallas
@to_be_elizabeth
@OncologyMarwarD
@Erman_Akkus
@SuyogCancer
@Lucarecco
@DrYukselUrun
@E_de_Azambuja
@GaiaGriguolo
@ozdogan_md
@MarioBalsaMD
@Dr_Oncologista
@Dr_ElvinaA
@ArmandOrlandi
@raffcolo
@hoperugo
@ElisaAgostinett
@ErikaHamilton9
@OncBrothers
@BianchiniGP
@antgiorda
@elmayermd
@Dr_Ivanoncologo
@LoiSher
@matteolambe
@tompowles1
@nataliagandur
@zapatalaguadomd
@dralvaropinto
@RKSayyid
@_ShankarSiva
@TiansterZhang
@MathewGWilson
@cdanicas
@DrRishabhOnco
@chavarriagaj
@ByMadeleineA
@docjavip
@Timothee_MD
@mirrorsmed
@weoncologists
@Dr_Aggen
@davidmarmolejo
@OrozcoBelinchon
@JyotiBajpai01
0
3
9
1,043
🚨Oncology: Here & Now🚨
An honor to discuss such important topics with the great @dandanmena from @UroTeragLATAM ✨
@wroclawski_uro @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala
@anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis
@Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
An honor to discuss such important topics with the great @dandanmena from @UroTeragLATAM ✨
@wroclawski_uro @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala
@anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis
@Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
Dear Colleagues at #ESMO25
Oncology: Here & Now is BACK ‼️
S2E1 GU Oncology 🚨
Listen Here: youtu.be/FSrJ5iL3F-c?si…
Join @bavilima 🇧🇷& @dandanmena 🇲🇽 on this Great Webcast as they discuss #ProstateCancer :
✅Rationale between BULLSEYE🎯 Trial
✅Difference Between Lutetium & Terbium
✅Affatients with PET
and much much more..AVAILABLE NOW!!!
@crisbergerot
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@HHammersMD
@ravikanesvaran
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@scserendipity1
@Silke_Gillessen
@tompowles1
@BraunMDPhD
@cdanicas
@brian_rini
#OncoAlertAF
@nataliagandur
@acampsmalea
@BRicciutiMD
@yekeduz_emre
@HHorinouchi
@FadiHaddad_MD
@Abdallah81MD
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@bavilima
@realbowtiedoc
@Erman_Akkus
@Lucarecco
@GaiaGriguolo
@JankovicK
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@OscarTahuahua
@BenWestphalen
@NiuSanford
0
8
12
1,246
Bárbara Melão, MD, PhD retweeted
🎯Patient individualisation is a Must! For Patient selection and follow up! The aim is that the Patient live longer BUT also BETTER 🥇 #qualityoflife #PSMAddition #ESMO25 #prostatacancer @DrScottTagawa
1
9
16
3,094
Bárbara Melão, MD, PhD retweeted
Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science
6
89
172
18,416
Dear Colleaguest at #ESMO25
A warm invite to our Flagship Event: REGISTER👉 oncoalert.m-pages.com/rnaYzs/the-5th…
OncoAlert, ESGO, ESSO, MASCC, SIOG, and our esteemed faculty invite you to the 2026 #OncoAlertColloquium!
Experience the very best in oncology delivered over 7 days, with each ific tumor type.
🗓 When: First week of February 2026
📋 Registration: Now open for the 6th Annual Colloquium
#BreastCancer #LungCancer #GynOnc #Melanoma #ProstateCancer #GastricCancer #BladderCancer #KidneyCancer and more
Sign up today, and we’ll send you a reminder as the event approaches.
Our 2025 Faculty
@hoperugo 🇺🇸
@ErikaHamilton9 🇺🇸
@Silke_Gillessen 🇨🇭
@GillSharlene 🇨🇦
@DrBetofMDPhD 🇺🇸
@CF_PC_OvCaGroup 🇬🇧
@NicoloBizzarri 🇮🇹
@GlopesMd 🇺🇸
@Icro_Meattini 🇮🇹
@maryam_lustberg 🇺🇸
@DrSGraff 🇺🇸
@CathyEngMD 🇺🇸
@DrJNaidoo 🇮🇪
@matteolambe 🇮🇹
@UmbertoMalapel1 🇮🇹
@agz_eriksson 🇳🇴
@DrRaulCordoba 🇪🇸
@PGrivasMDPhD 🇺🇸
@ARosen380 🇺🇸
Roberto Salgado 🇧🇪
Declan Murphy 🇦🇺
Renu Eapen 🇦🇺
@VincentWenxinXu 🇺🇸
Fatima Cardoso 🇵🇹
@HenningWillers 🇺🇸
@BenWestphalen 🇩🇪
@E_de_Azambuja 🇧🇪
@kevinpunie 🇧🇪
@EnriqueSoto8 🇺🇸
@NiuSanford 🇺🇸
@CharuAggarwalMD 🇺🇸
@MelissaLoh21 🇺🇸
@KatieKeaneMD 🇺🇸
@Abdallah81MD 🇺🇸
@FernandoOnco 🇧🇷
@nataliagandur 🇦🇷
@rooogerthat 🇵🇭
@AStrojnaMD 🇩🇪
Annamaria Ferrero🇮🇹
Alejandra Martinez🇫🇷🇪🇸
@CoquardRay 🇫🇷
Maaike Oonk🇳🇱
@ChargariC 🇫🇷
Kim Hulscher🇳🇱
@EngageEsgo
@TanjaSpanic 🇸🇮
@ElisaAgostinett 🇮🇹
@realbowtiedoc 🇺🇸
@BiagioRicciutMD 🇺🇸
Partners
@ESSOnews
@ESGO_society
@CancerCareMASCC
@SIOGorg
0
5
6
1,961
#ESMO25 #KidneyCancer
@brian_rini discuss OPTIC Trial 👉 RNAseq-guided therapy in mccRCC
@wroclawski_uro @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala
@anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis
@Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
@brian_rini discuss OPTIC Trial 👉 RNAseq-guided therapy in mccRCC
@wroclawski_uro @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala
@anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis
@Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
Dear Colleagues at #ESMO25 An Honor to introduce our Faculty 🚨 @brian_rini Discussing the OPTIC Trial in #KidneyCancer
2591O - Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a phase II trial of a novel presented at ESMO Berlin by @DrScottHaake
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
0
5
7
1,056
Bárbara Melão, MD, PhD retweeted
The #OncoAlert5k 🚨Berlin🇩🇪
HUGE THANKS to all of our Friends
We Are ALL OncoAlert 🌐
@DrVilmaPBarcia
@benjiwal
@vibasilios
@marcoscl
@sevincballi
@SandroCavallero
@Gino_K_In_USC
@MayanaNavarro
@DonjetaZeqa
@LouisaHempel
@CameliaDeak
@CameliaDeak
@CathyEngMD icevic
@LaurenMachos
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @bmassutis @matteolambe @Icro_Meattini
HUGE THANKS to all of our Friends
We Are ALL OncoAlert 🌐
@DrVilmaPBarcia
@benjiwal
@vibasilios
@marcoscl
@sevincballi
@SandroCavallero
@Gino_K_In_USC
@MayanaNavarro
@DonjetaZeqa
@LouisaHempel
@CameliaDeak
@CameliaDeak
@CathyEngMD icevic
@LaurenMachos
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @bmassutis @matteolambe @Icro_Meattini
4
15
37
6,129
#BladderCancer #ESMO25
@OncoAlert coverage and @PGrivasMDPhD with the highlights from
✨Keynote 905
✨DV + Toripalimab
✨IMvigor011
@wroclawski_uro @philippespiess
@WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala
@anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis
@Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
@OncoAlert coverage and @PGrivasMDPhD with the highlights from
✨Keynote 905
✨DV + Toripalimab
✨IMvigor011
@wroclawski_uro @philippespiess
@WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala
@anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero @davidmuniz @fsabino_onco @jardim_denis
@Martin_AngelMD @fedelosco @LauBernalOnc @raymanneh @karima_oualla
Dear Colleagues at #ESMO25
A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin
✅ Keynote 905
✅ Disitamab vedotin (DV) plus toripalimab
✅ IMvigor011
And @nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
@PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas
@yekeduz_emre @DrYukselUrun
@karima_oualla @giannatempopatr
0
7
9
1,511
Great #ESMO25 coverage from this amazing @OncoAlert team🚨
Stay tuned ‼️
@OncoAlert @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett @to_be_elizabeth @ADesaiMD
Stay tuned ‼️
@OncoAlert @OncoReporte @gilmorgan @nataliagandur @FernandoOnco @realbowtiedoc @DenizCanGuven1 @BiagioRicciutMD @ElisaAgostinett @dr_yakupergun @yekeduz_emre @lungoncdoc @ElisaAgostinett @to_be_elizabeth @ADesaiMD
We are in Berlin for #ESMO25
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials. smartphone: direct, no fluff and always relevant.
#OncoAlertAF
🇺🇸 @WeOncologists
🇧🇪 @ElisaAgostinett
🇦🇷 @nataliagandur
🇮🇹 @to_be_elizabeth
🇫🇷 @acampsmalea
🇺🇸 @BRicciutiMD
🇯🇵 @HHorinouchi
🇺🇸 @Abdallah81MD
🇧🇷 @bavilima
🇧🇷 @FernandoOnco
🇺🇸 @realbowtiedoc
🇹🇷 @Erman_Akkus
🇮🇹 @Lucarecco
🇮🇹 @GaiaGriguolo
🇷🇸 @JankovicK
🇪🇸 @MarioBalsaMD
🇪🇸 @DrMirallas
🇺🇸 @GIMedOnc
🇹🇷 @UOzkerim
🇮🇳 @DrRishabhOnco
🇲🇽 @ReginaBarCar
🇨🇴 @Onco_Cifu88
Ping Faculty
@matteolambe
@PGrivasMDPhD
@E_de_Azambuja
@amerseburger
@Icro_Meattini
@montypal
@crisbergerot
@aftimosp
0
5
9
1,141
Bárbara Melão, MD, PhD retweeted
🟠 LBA109 – DISCUS: 3 vs 6 cycles of platinum-based chemotherapy before Avelumab maintenance in advanced urothelial carcinoma
👨⚕️ Presented by Dr. Enrique Grande (@drenriquegrande)
#ESMO25 @OncoAlert @MedicalwatchHQ
➡️ Phase II DISCUS compared 3 vs 6 cycles of platinum-based r carbo/gem) before Avelumab maintenance in untreated advanced UC.
⚡ N = 267; 133 (3C) vs 134 (6C).
⭐ QoL improved with 3C → +8.5 points (p = 0.016).
💡 OS: 18.9 mo in both arms (HR 1.15; p = 0.56).
👉 PFS: 8.0 vs 9.0 mo (HR 1.05; p = 0.79).
⚠️ Grade 3–4 TRAEs: 11.9% (3C) vs 15.7% (6C).
🔆 Conclusion: Shorter induction (3 cycles) followed by Avelumab maintenance preserves efficacy while improving QoL — supporting treatment de-escalation in advanced UC.
@DrChoueiri @MyriamChalabi @myESMO #Berlin
🔗 @montypal @DrDanielHeng @VivekSubbiah @HHammersMD @Uromigos
#BladderCancer #Avelumab #DISCUS #GU25 #ESMO25 #Oncology #ClinicalTrials
👨⚕️ Presented by Dr. Enrique Grande (@drenriquegrande)
#ESMO25 @OncoAlert @MedicalwatchHQ
➡️ Phase II DISCUS compared 3 vs 6 cycles of platinum-based r carbo/gem) before Avelumab maintenance in untreated advanced UC.
⚡ N = 267; 133 (3C) vs 134 (6C).
⭐ QoL improved with 3C → +8.5 points (p = 0.016).
💡 OS: 18.9 mo in both arms (HR 1.15; p = 0.56).
👉 PFS: 8.0 vs 9.0 mo (HR 1.05; p = 0.79).
⚠️ Grade 3–4 TRAEs: 11.9% (3C) vs 15.7% (6C).
🔆 Conclusion: Shorter induction (3 cycles) followed by Avelumab maintenance preserves efficacy while improving QoL — supporting treatment de-escalation in advanced UC.
@DrChoueiri @MyriamChalabi @myESMO #Berlin
🔗 @montypal @DrDanielHeng @VivekSubbiah @HHammersMD @Uromigos
#BladderCancer #Avelumab #DISCUS #GU25 #ESMO25 #Oncology #ClinicalTrials
1
20
33
6,609
Bárbara Melão, MD, PhD retweeted
🟠 LBA108 – POTOMAC: Durvalumab + BCG vs BCG alone in BCG-naïve high-risk NMIBC
👩⚕️ Presented by Dr. Maria De Santis
#ESMO25 @OncoAlert @MedicalwatchHQ
➡️ POTOMAC (Phase III, randomized, open-label, international) evaluated Durvalumab + BCG induction + maintenance (I+M) vs BCG e, high-risk NMIBC.
⚡ Median follow-up: 60.7 mo (N = 1018).
⭐ Primary endpoint – DFS: met with 32% risk reduction of recurrence or death → HR 0.68 (95% CI 0.50–0.93; p = 0.015).
💡 24-mo DFS: 86.5% (D+BCG I+M) vs 81.6% (BCG I+M).
👉 Secondary endpoint – D+BCG induction-only arm not significant (HR 1.14).
⚠️ Grade 3/4 TRAEs: 21% (D+BCG I+M) vs 4% (BCG I+M); no treatment-related deaths.
🔆 Take-home: One year of Durvalumab with BCG (I+M) delivers a statistically and clinically meaningful DFS benefit and emerges as a new therapeutic option for BCG-naïve high-risk NMIBC.
@DrChoueiri @MyriamChalabi @myESMO #Berlin
🔗 @PGrivasMDPhD @tompowles1 @Silke_Gillessen @drenriquegrande @urotoday
#BladderCancer #NMIBC #Durvalumab #POTOMAC #GU25 #ESMO25 #Oncology #ClinicalTrials
👩⚕️ Presented by Dr. Maria De Santis
#ESMO25 @OncoAlert @MedicalwatchHQ
➡️ POTOMAC (Phase III, randomized, open-label, international) evaluated Durvalumab + BCG induction + maintenance (I+M) vs BCG e, high-risk NMIBC.
⚡ Median follow-up: 60.7 mo (N = 1018).
⭐ Primary endpoint – DFS: met with 32% risk reduction of recurrence or death → HR 0.68 (95% CI 0.50–0.93; p = 0.015).
💡 24-mo DFS: 86.5% (D+BCG I+M) vs 81.6% (BCG I+M).
👉 Secondary endpoint – D+BCG induction-only arm not significant (HR 1.14).
⚠️ Grade 3/4 TRAEs: 21% (D+BCG I+M) vs 4% (BCG I+M); no treatment-related deaths.
🔆 Take-home: One year of Durvalumab with BCG (I+M) delivers a statistically and clinically meaningful DFS benefit and emerges as a new therapeutic option for BCG-naïve high-risk NMIBC.
@DrChoueiri @MyriamChalabi @myESMO #Berlin
🔗 @PGrivasMDPhD @tompowles1 @Silke_Gillessen @drenriquegrande @urotoday
#BladderCancer #NMIBC #Durvalumab #POTOMAC #GU25 #ESMO25 #Oncology #ClinicalTrials
0
11
38
3,438
Bárbara Melão, MD, PhD retweeted
At @myESMO #esmo2025 Berlin, I had the privilege to present the #ALBAN trial (GETUG–AFU 37), an academic phase III study led by @AFUrologie & @GETUG_Unicancer @LaCarine1 together with my outstanding co-PI @y_loriot ,co-investigators @PignotG @champiatMD @PrRomainMATHIEU @ThgieParis and many others across 🇫🇷🇧🇪🇪🇸.
Atezolizumab + BCG did not improve EFS vs BCG alone (HR 0.98; 95% CI 0.71–1.36).
The result was negative across all subgroups, including CIS.
Higher ≥G3 TRAEs were observed in the combination arm.
These findings highlight that in localized #BladderCancer, systemic toxicity assessment remains a key endpoint to balance benefit and risk.
Proud of this collective academic journey started in 2017 — despite the global BCG shortage and COVID-19 — and now published in @Annals_Oncology
📄 doi.org/10.1016/j.anno… with the financial support of @Roche
#NMIBC #ESMO25 #OncoUrology #ClinicalResearch @AFUrologie @afufuro @GETUG_Unicancer #EAUguidelines @Uroweb @AmerUrological @ASCO @Uromigos @tompowles1 @DrChoueiri
Atezolizumab + BCG did not improve EFS vs BCG alone (HR 0.98; 95% CI 0.71–1.36).
The result was negative across all subgroups, including CIS.
Higher ≥G3 TRAEs were observed in the combination arm.
These findings highlight that in localized #BladderCancer, systemic toxicity assessment remains a key endpoint to balance benefit and risk.
Proud of this collective academic journey started in 2017 — despite the global BCG shortage and COVID-19 — and now published in @Annals_Oncology
📄 doi.org/10.1016/j.anno… with the financial support of @Roche
#NMIBC #ESMO25 #OncoUrology #ClinicalResearch @AFUrologie @afufuro @GETUG_Unicancer #EAUguidelines @Uroweb @AmerUrological @ASCO @Uromigos @tompowles1 @DrChoueiri
7
28
82
10,553
Bárbara Melão, MD, PhD retweeted
💥 The @OncoAlert #GUOncology team has once again delivered an outstanding lineup! 🙌
Excited to discuss these studies live at #ESMO25 Berlin 🇩🇪
From PSMAaddition to RAMPART and KEYNOTE-905, the GU field is stronger than ever.
Which one are you most looking forward to? 💬
🌍 team:
#OncoAlertAF
🇺🇸 @WeOncologists
🇧🇪 @ElisaAgostinett
🇦🇷 @nataliagandur
🇮🇹 @to_be_elizabeth
🇫🇷 @acampsmalea
🇺🇸 @BRicciutiMD
🇯🇵 @HHorinouchi
🇺🇸 @Abdallah81MD
🇧🇷 @bavilima
🇧🇷 @FernandoOnco
🇺🇸 @realbowtiedoc
🇹🇷 @Erman_Akkus
🇮🇹 @Lucarecco
🇮🇹 @GaiaGriguolo
🇷🇸 @JankovicK
🇪🇸 @MarioBalsaMD
🇪🇸 @DrMirallas
🇺🇸 @GIMedOnc
🇹🇷 @UOzkerim
🇮🇳 @DrRishabhOnco
🇲🇽 @ReginaBarCar
Excited to discuss these studies live at #ESMO25 Berlin 🇩🇪
From PSMAaddition to RAMPART and KEYNOTE-905, the GU field is stronger than ever.
Which one are you most looking forward to? 💬
🌍 team:
#OncoAlertAF
🇺🇸 @WeOncologists
🇧🇪 @ElisaAgostinett
🇦🇷 @nataliagandur
🇮🇹 @to_be_elizabeth
🇫🇷 @acampsmalea
🇺🇸 @BRicciutiMD
🇯🇵 @HHorinouchi
🇺🇸 @Abdallah81MD
🇧🇷 @bavilima
🇧🇷 @FernandoOnco
🇺🇸 @realbowtiedoc
🇹🇷 @Erman_Akkus
🇮🇹 @Lucarecco
🇮🇹 @GaiaGriguolo
🇷🇸 @JankovicK
🇪🇸 @MarioBalsaMD
🇪🇸 @DrMirallas
🇺🇸 @GIMedOnc
🇹🇷 @UOzkerim
🇮🇳 @DrRishabhOnco
🇲🇽 @ReginaBarCar
0
11
35
2,626
Bárbara Melão, MD, PhD retweeted
🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj @PCFnews @OncoAlert @urotoday
5
69
130
14,885